252 related articles for article (PubMed ID: 25430438)
1. Central modulation of cyclosporine-induced hypertension.
El-Gowelli HM; El-Mas MM
Naunyn Schmiedebergs Arch Pharmacol; 2015 Mar; 388(3):351-61. PubMed ID: 25430438
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension.
Zhang W; Victor RG
Am J Hypertens; 2000 Sep; 13(9):999-1004. PubMed ID: 10981550
[TBL] [Abstract][Full Text] [Related]
3. Sympathetic neural mechanisms of cyclosporine-induced hypertension.
Sander M; Lyson T; Thomas GD; Victor RG
Am J Hypertens; 1996 Nov; 9(11):121S-138S. PubMed ID: 8931845
[TBL] [Abstract][Full Text] [Related]
4. Interruption of central neuronal pathway of imidazoline I1 receptor mediates the hypertensive effect of cyclosporine in rats.
El-Mas MM; Omar AG; Helmy MM; Mohy El-Din MM
Brain Res; 2009 Jan; 1248():96-106. PubMed ID: 19028461
[TBL] [Abstract][Full Text] [Related]
5. Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine.
Reis F; Parada B; Teixeira de Lemos E; Garrido P; Dias A; Piloto N; Baptista S; Sereno J; Eufrásio P; Costa E; Rocha-Pereira P; Santos-Silva A; Figueiredo A; Mota A; Teixeira F
Transplant Proc; 2009 Apr; 41(3):868-73. PubMed ID: 19376375
[TBL] [Abstract][Full Text] [Related]
6. Neurotoxicity of calcineurin inhibitors: impact and clinical management.
Bechstein WO
Transpl Int; 2000; 13(5):313-26. PubMed ID: 11052266
[TBL] [Abstract][Full Text] [Related]
7. The protective effect of neutralizing high-mobility group box1 against chronic cyclosporine nephrotoxicity in mice.
Park HS; Kim EN; Kim MY; Lim JH; Kim HW; Park CW; Yang CW; Jin DC; Choi BS
Transpl Immunol; 2016 Feb; 34():42-9. PubMed ID: 26603313
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
9. Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report.
Pascual J; Fernández AM; Marcén R; Ortuño J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii38-41. PubMed ID: 16815857
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of acute and sustained cyclosporine and tacrolimus on sympathetic nerve activity.
Klein IH; Abrahams AC; van Ede T; Oey PL; Ligtenberg G; Blankestijn PJ
J Hypertens; 2010 Sep; 28(9):1928-34. PubMed ID: 20577127
[TBL] [Abstract][Full Text] [Related]
11. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.
Sommerer C; Schaier M; Morath C; Schwenger V; Rauch G; Giese T; Zeier M
Trials; 2014 Dec; 15():489. PubMed ID: 25494823
[TBL] [Abstract][Full Text] [Related]
12. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus.
Fuchs U; Klein S; Zittermann A; Ensminger SM; Schulz U; Gummert JF
Ann Transplant; 2014 Jun; 19():300-4. PubMed ID: 24953848
[TBL] [Abstract][Full Text] [Related]
13. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
14. Is cyclosporine withdrawal a therapeutic option in renal transplant recipients with chronic allograft dysfunction?
Ducloux D
Minerva Urol Nefrol; 2003 Mar; 55(1):81-9. PubMed ID: 12773969
[TBL] [Abstract][Full Text] [Related]
15. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
[TBL] [Abstract][Full Text] [Related]
16. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
17. Nicardipine as antihypertensive therapy in liver transplant recipients: results of long-term use.
Duvoux C; Cherqui D; Di Martino V; Métreau JM; Salvat A; Lauzet JY; Fagniez PL; Dhumeaux D
Hepatology; 1997 Feb; 25(2):430-3. PubMed ID: 9021959
[TBL] [Abstract][Full Text] [Related]
18. Hypertension after cardiac transplantation: pathophysiology and management.
Sander M; Victor RG
Curr Opin Nephrol Hypertens; 1995 Sep; 4(5):443-51. PubMed ID: 8564450
[TBL] [Abstract][Full Text] [Related]
19. The safety of calcineurin inhibitors for kidney-transplant patients.
Malvezzi P; Rostaing L
Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
[TBL] [Abstract][Full Text] [Related]
20. [Effect of immunosuppressive treatment on diurnal profile of blood pressure].
Pilecki T; Paczek L; Senatorski G; Wyzgał J; Zegarska J; Rowiński W; Szmidt J
Pol Merkur Lekarski; 2002 Nov; 13 Suppl 1():37-40; discussion 40-1. PubMed ID: 12621780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
